Low Prognosis of Brain Tumors to Spur Industry Interest in Diagnostics and Therapeutics

Advances in diagnostics and therapeutics to improve the management of brain tumors have been varied and clinically promising. The prognosis of most common brain tumors have been presenting challenges to researchers and clinicians alike. Despite the strides in surgery and diagnostics, the rising incidence of brain tumor has been concerning to global health care systems. The low survival rates of patients with aggressive brain tumors and growing cases of intracranial malignancies have further made the scenario alarming. Though rapid advances have been made in understanding the genetic, epigenetic, and micro-environmental features underlying brain cells, researchers have faced several problems in unveiling new therapies in the market. The rarity of the brain tumors in itself is a big factor to resist even the most novel therapies, thereby making the pace of commercialization of brain tumor therapeutics strikingly stilted. Low level of interest among pharmaceutical industry .

Get Sample Copy of this Report @ 

https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1181

Most notably, the global healthcare industry and oncologists have seen large unmet need in the market in the management of glioblastoma multiforme (GBM) tumors. To address the need, researchers around the world are testing new technologies based on drug-containing nanoparticles.

Researchers Test New Methods based on Bioengineered Nanomaterials

Technological developments in the brain tumor diagnostics and therapeutics market have been marked by the advent of promising drug delivery methods put to test to overcome the unique blood-brain barrier. Adoption of methods based on bioengineered nanomaterials has aimed at increasing drug delivery effectiveness and overcoming systemic side-effects. This has also expanded the scope of the brain tumor diagnostics and therapeutics. New methods of encapsulating hydrophobic drugs and for delivery of the cargo inside the tumor are boosting the brain tumor diagnostics and therapeutics.

Several clinical studies have helped drug makers expand the array of nanomedicines that can pave way to novel therapies, thereby bringing new approaches in the brain tumor diagnostics and therapeutics market. Strides made by CNS drug delivery have considerably expanded the prospect.

Check Table of Contents of this Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1181

Developed nations notably the U.K. and U.K. have been laying increasing emphasis on the management of brain tumors, expanding the window of possibilities in the brain tumor diagnostics and therapeutics market. Seeing various challenged with the eye of ‘call-to-arms’ approach might revitalize brain tumor research pipeline.

Brain Tumor Diagnostics and Therapeutics Market Recent business strategies in healthcare sector 2025

Global Brain Tumor Diagnostics and Therapeutics Market: Snapshot

The global market for the diagnostics and therapeutics is gaining traction from a number of factors, such as increasing prevalence of brain cancer, innovations in drug delivery to brain cancer cells, and widespread market for the treatment of brain cancer as well as its associated symptoms. On the other hand, the lack of brain cancer specific drugs, increasing use of generics in chemotherapy, and utterly high cost of brain tumor diagnosis and treatment are a few important challenges faced by the market before attaining its true potential. Nevertheless, in the near future, the vendors of this market are expected to gain new opportunities by improving the technology to reach the cancer tumor at unreachable parts of the brain, although surgery currently remains the most effective mode of treatment.

Based on cancer type, the global brain tumor diagnostics and therapeutics market can be segment into glioma including oligodendroglioma, astrocytoma, choroid plexus papilloma, and ependymoma, medulloblastoma, meningioma, schwannomas, and pituitary adenoma. On the basis of therapeutics, this market can be categorized into brain cancer including radiation therapy, chemotherapy, and targeted therapy. Geographically, the report takes stock of the potential of all important regions such as North America, Asia Pacific, and Europe.

Request Sample Copy of the Report @

https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1181

This report on the global brain tumor diagnostics and therapeutics market has been developed by a group of professional market research analysts, with a solitary goal to represent the current scenario as well as the future prospects of the market to the stakeholders connected to the value chain. A number of leading companies operating in this market have also been profiled to highlight the competitive landscape.

Global Brain Tumor Diagnostics and Therapeutics Market: Overview

Increased prevalence of symptoms associated with brain tumor has led to a growing demand for tests detecting the presence of tumors. Some of the common types of tests used for the diagnosis of brain tumor are magnetic resonance imaging (MRI), myelogram, electroencephalography (EEG),  tissue sampling or biopsy of surgical removal of a tumor, CT scan, cerebral angiogram or cerebral anteriogram, molecular testing, positron emission tomography (also called PET or PET-CT scan), and neurocognitive assessment.

The growth drivers, opportunities, deterrents, and recent developments in the global market for brain tumor diagnostics and therapeutics have been analyzed in details. The report presents value chain analysis, the supply and demand ratio, market attractiveness, and the past and projected leading market segments. The prominent vendors have been evaluated in depth, considering their market shares, product portfolios, and recent business strategies.

Request TOC of the Report @

https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1181

Global Brain Tumor Diagnostics and Therapeutics Market: Drivers and Restraints

Recently, the healthcare sector has been displaying increasing public-private partnerships. These partnerships will prove to be beneficial for the growth of the global brain tumor diagnostics and therapeutics market as they are contributing towards the modernization of radiology and diagnostic imaging services. Research activities in the area of molecular diagnostics aimed at understanding cell biology and recognizing gene mutations related to malignancy are expected to boost growth. Technological advancements, increasing consumer base, advanced healthcare infrastructures, and growing health awareness among people are some of the major growth drivers of the global brain tumor diagnostics and therapeutics market.

On the other hand, the high cost of these tests and lack of trained personnel might restrain the growth of the global brain tumor diagnostics and therapeutics market. Nevertheless, opportunities are likely to materialize from the emergence of new technologies such as chemical exchange saturation transfer (CEST) and sodium magnetic resonance imaging (Na MRI). These technologies not only aid in the diagnosis of tumors, but also in therapies treating them.

Read Comprehensive Overview of Report @

https://www.tmrresearch.com/brain-tumor-diagnostics-therapeutics-market 

Based on types of tumor, the anaplastic astrocytoma, anaplastic oligodendroglioma, low-grade (diffuse) astrocytoma, ependymoma, glioblastoma, and oligodendroglioma can be the major segments.

Global Brain Tumor Diagnostics and Therapeutics Market: Regional Outlook

Based on region, the global brain tumor diagnostics and therapeutics market can be segmented into the Middle East and Africa, Latin America, North America, Asia Pacific, and Europe. North America, with the U.S at the forefront, is expected to witness significant growth. The increasing demand for brain tumor diagnostics and therapeutics from this region can be attributed to the rising incidence of brain tumors. According to the Central Brain Tumor Registry, the U.S. might witness approximately 79,270 new cases of primary non-malignant and malignant brain and CNS tumors by the end of 2017.

Furthermore, Asia Pacific is slated to expand considerably over the forecast period, as the awareness about the availability and significance of these tests is gradually spreading. The healthcare expenditures and per capita incomes of people in countries across Asia Pacific are also rising, promising further expansion of the brain tumor diagnostics and therapeutics market in the region.

Companies Mentioned in the Report

Some of the major market players operating in the global brain tumor diagnostics and therapeutics market are Philips Healthcare, Roche Diagnostics, GE Healthcare, Toshiba Corporation, Carestream Health, Bristol Myer Squibb, Hitachi, Ltd., and Siemens Healthineers.

Brain Tumor Diagnostics and Therapeutics Market: Research in Molecular Diagnostics Aimed at Cell Biology Driving Growth

San Francisco, California, November 06, 2017: The growing number of cases where there exists symptoms associated with brain tumor has led to a need for tests which can detect the presence of tumors, .states TMR Research in its latest report. The report is titled “Brain Tumor Diagnostics and Therapeutics Market – Global Industry Analysis, Size, Share, Trends, Analysis, Growth, and Forecast 2017 – 2025.” According to the report the brain tumor diagnostics and therapeutics market is witnessing a high growth on account of the growing prevalence of brain cancer, widespread market for the treatment of brain cancer and associated symptoms, as well as innovations in drug delivery. Some of the most commonly used tests for the diagnosis of Brain Tumor include magnetic reasoning imaging (MRI), biopsy or tissue sampling, CT scan, electroencephalography (EEG), cerebral angiogram of cerebral anteriogram, positron emission tomography (PET), molecular testing, and neuro cognitive assessment.

According to the report, the trend of public private partnerships in the healthcare sector will prove to be beneficial for the growth of the brain tumor diagnostics and therapeutics market because this is enabling the modernization of radiology and diagnostic imaging services. Another factor which will boost the growth of the market is the increasing research activities in the area of molecular diagnostics that are aimed at cell biology and recognizing gene mutations related to malignancy. Other growth drivers for the market include increasing consumer base, technological advancements, advanced healthcare infrastructure, and increasing awareness and concern among people regarding their health.

The report not only discusses the growth drivers but also discusses the various factors that are expected to challenge the growth trajectory of the brain tumor diagnostics and therapeutics market. One of the key factors that is expected to deter the market’s growth is the high cost of these tests. Another factor that will restrain the growth of the market is the lack of trained personnel. The growing use of generics in chemotherapy and the lack of brain cancer specific drug other factors that will hamper the growth of the market. However, various growth opportunities are expected to emerge on account of the development of new technologies such as sodium magnetic resonance imaging (Na MRI) and chemical exchange saturation transfer (CEST). These technologies assist the therapies treating the tumor as well as in the diagnosis of tumors. It is also expected that the improvement in technology will enable access to cancer tumors at unreachable parts of the brain.

On the basis of geography, North America is expected to be the leading regional segment, with the US in the forefront. As per the Central Brain Tumor Registry, there have been approximately 79,270 new cases of primary non malignant and malignant brain and CNS tumors in the year 2017. This growing incidence of brain tumor in the country is expected to drive the growth of the North American brain tumor diagnostics and therapeutics market. Apart from North America, it is expected that Asia Pacific will expand at a favorable pace during the forecast period on account of the growing awareness among the patients about the availability and significance of these tests. The health expenditure and the income of people in Asia Pacific is increasing and this is expected to further expand the growth of the brain tumor diagnostic and therapeutic market.

The report segments the market based on types of tumor into: the anaplastic astrocytoma, low-grade (diffuse) astrocytoma, anaplastic oligodendroglioma, ependymoma, oligodendroglioma, and glioblastoma.

The report profiles key players within the brain tumor diagnostics and therapeutics market for the purpose of study. Some of them are: Roche Diagnostics, Philips Healthcare, GE Healthcare, Carestream Health, Toshiba Corporation, Bristol Myer Squibb, Siemens Healthineers, and Hitachi, Ltd.

Get Sample Brochure of this Report Study

https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1181